Assembly Biosciences, Inc.
ASMB Healthcare Biotechnology
Assembly Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72.3 million, up 153.5% from fiscal 2024. In the quarter to June 2026, revenue grew 38.9%, EPS grew 85.0% and free cash flow grew 7.58%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ASMB
Assembly Biosciences, Inc. (ASMB) Altman Z-score
Assembly Biosciences, Inc.'s Altman Z-score for fiscal 2025 is 1.06, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 1.06 | 10.44 |
| FY2024 | −9.38 | (0.94) |
| FY2023 | −8.44 | (5.15) |
| FY2021 | −3.29 | (4.19) |
| FY2020 | 0.91 | (2.08) |
| FY2019 | 2.98 | (0.45) |
| FY2018 | 3.43 | (2.88) |
| FY2017 | 6.31 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.80 | — | 0.96 | |
| Retained earnings / total assets | (3.23) | — | −4.52 | |
| EBIT / total assets | (0.05) | — | −0.16 | |
| Market value of equity / total liabilities | 7.50 | — | 4.50 | |
| Sales / total assets | 0.28 | — | 0.28 | |
| Altman Z-score | Distress zone | 1.06 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −1.34 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ENTX Entera Bio Ltd. compare | 6.2× |
| ASMB Assembly Biosciences, Inc. | 1.1× |
| OVID Ovid Therapeutics compare | 0.2× |
| ARVN Arvinas, Inc. compare | −0.6× |
| AUTL Autolus Therapeutics PLC Sponsored ADR compare | −3.2× |
| MPLT MapLight Therapeutics, Inc. compare | — |
| EPRX Eupraxia Pharmaceuticals Inc. compare | — |
| YDES YD Bio Limited compare | — |
| RZLT Rezolute, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets